Restricted accessResearch articleFirst published online 2020-12
High-Frequency Application of Cationic Agents Containing Lubricant Eye Drops Causes Cumulative Corneal Toxicity in an Ex Vivo Eye Irritation Test Model
High-frequency applied cetalkonium chloride (CAC) and benzalkonium chloride (BAC) 0.02% did not hamper corneal healing in a living rabbit model of induced corneal erosion. In contrast, the ex vivo eye irritation test (EVEIT) shows inhibition of healing for these substances. In a systematic ex vivo reproduction of the in vivo experiments, we discuss the background of these differences.
Methods:
Excised rabbit corneas (n = 5 per group) were cultured in artificial anterior chambers (EVEIT). Four erosions were induced for each cornea before starting regular 21 installations/day over 3 days of (1) CAC containing eye drops (Cationorm®), (2) 0.02% BAC. Corneal fluorescein staining, quantification of glucose-/lactate consumption, and histology were performed.
Results:
BAC 0.02% treated corneas showed increased epithelial lesions from 10.13 ± 0.65 mm2 to 10 ± 0.8 mm2 on day 0, to 86.82 ± 5.18 mm2 (P < 0.0001) by day 3. After a trend toward smaller lesions for CAC on day 1, erosion sizes increased significantly by day 3 from 9.82 ± 0.30 mm2 to 29.51 ± 16.87 mm2 (P < 0.05). For 1 cornea, corneal erosions nearly disappeared on day 3 (0.89 mm2). Corneal lactate increased significantly for BAC and CAC, whereas glucose concentrations were unchanged. Histology revealed disintegration of the corneal structures for both compounds.
Conclusions:
The data underline the EVEIT as a predictive toxicity test to show side effects in a time-compressed manner. The consistency of these predictions was previously demonstrated by the EVEIT for BAC, phosphate buffer, and others. The EVEIT is suited for a chronic application prediction of tolerability and toxic side effects of eye drops in particular, and other chemicals in general.
Get full access to this article
View all access options for this article.
References
1.
CraigJ.P., NicholsK.K., AkpekE.K.et al. TFOS DEWS II definition and classification report. Ocul. Surf. 15:276–283, 2017.
2.
FarrandK.F., FridmanM., StillmanI.O., and SchaumbergD.A.Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am. J. Ophthalmol. 182:90–98, 2017.
3.
HanS.B., HyonJ.Y., WooS.J., LeeJ.J., KimT.H., and KimK.W.Prevalence of dry eye disease in an elderly Korean population. Arch. Ophthalmol. 129:633–638, 2011.
4.
BegleyC.G., CafferyB., ChalmersR.L., and MitchellG.L.Use of the dry eye questionnaire to measure symptoms of ocular irritation in patients with aqueous tear deficient dry eye. Cornea. 21:664–670, 2002.
5.
SchiffmanR.M., ChristiansonM.D., JacobsenG., HirschJ.D., and ReisB.L.Reliability and validity of the Ocular Surface Disease Index. Arch. Ophthalmol. 118:615–621, 2000.
6.
DoughtyM.J., and GlavinS.Efficacy of different dry eye treatments with artificial tears or ocular lubricants: a systematic review. Ophthalmic Physiol. Opt. 6:573–583, 2009.
7.
LaunayP.S., ReboussinE., LiangH.et al. Ocular inflammation induces trigeminal pain, peripheral and central neuroinflammatory mechanisms. Neurobiol. Dis. 88:16–28, 2016.
8.
ZhangR., ParkM., RichardsonA.et al. Dose-dependent benzalkonium chloride toxicity imparts ocular surface epithelial changes with features of dry eye disease. Ocul. Surf. 1:158–169, 2020.
9.
MehannaC., BaudouinC., and Brignole-BaudouinF.Spectrofluorometry assays for oxidative stress and apoptosis, with cell viability on the same microplates: a multiparametric analysis and quality control. Toxicol. In Vitro. 5:1089–1096, 2011.
10.
JaenenN., BaudouinC., PouliquenP., ManniG., FigueiredoA., and ZeyenT.Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur. J. Ophthalmol. 3:341–349, 2007.
11.
KuppensE.V., de JongC.A., StolwijkT.R., de KeizerR.J., and van BestJ.A.Effect of timolol with and without preservative on the basal tear turnover in glaucoma. Br. J. Ophthalmol. 4:339–342, 1995.
12.
XiongC., ChenD., LiuJ.et al. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride. Invest. Ophthalmol. Vis. Sci. 49:1850–1856, 2008.
13.
PinheiroR., PanfilC., SchrageN., and DutescuR.M.Comparison of the lubricant eyedrops Optive®, Vismed Multi®, and Cationorm® on the corneal healing process in an ex vivo model. Eur. J. Ophthalmol. 25:379–384, 2015.
14.
FrentzM., GossM., ReimM., and SchrageN.F.Repeated exposure to benzalkonium chloride in the Ex Vivo Eye Irritation Test (EVEIT): observation of isolated corneal damage and healing. Altern. Lab. Anim. 36:25–32, 2008.
15.
SchrageN., FrentzM., and SpoelerF.The Ex Vivo Eye Irritation Test (EVEIT) in evaluation of artificial tears: purite-preserved versus unpreserved eye drops. Graefes. Arch. Clin. Exp. Ophthalmol. 250:1333–1340, 2012.
16.
BallsM., GoldbergA.M., and FentemJ.H.The three Rs: the way forward: the report and recommendations of ECVAM Workshop 11. Altern. Lab. Anim. 23:838–866, 1995.
17.
DaullP., RaymondE., FerailleL., and GarrigueJ.S.Safety and tolerability of overdosed artificial tears by abraded rabbit corneas. J. Ocul. Pharmacol. Ther. 34:670–676, 2018.
18.
PinheiroR., PanfilC., SchrageN., and DutescuR.M.The impact of glaucoma medications on corneal wound healing. J. Glaucoma. 25:122–127, 2016.
19.
DutescuR.M., PanfilC., and SchrageN.Comparison of the effects of various lubricant eye drops on the in vitro rabbit corneal healing and toxicity. Exp. Toxicol. Pathol. 69:123–129, 2017.
20.
SpölerF., KrayO., KrayS., PanfilC., and SchrageN.F.The Ex Vivo Eye Irritation Test as an alternative test method for serious eye damage/eye irritation. Altern. Lab. Anim. 43:163–179, 2015.
21.
NagaiN., MuraoT., OkamotoN., and ItoY.Comparison of corneal wound healing rates after instillation of commercially available latanoprost and travoprost in rat debrided corneal epithelium. J. Oleo. Sci. 59:135–141, 2010.
22.
AiharaM., OtaniS., KozakiJ., UnokiK., TakeuchiM., MinamiK., and MiyataK.Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost. J. Glaucoma. 21:60–64, 2012.
23.
AiharaM., IkedaY., MizoueS., ArakakiY., KitaN., and KobayashiS.NEXTraKT Study Group. Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost. J. Glaucoma. 25:e610–e614, 2016.
24.
KimJ.H., KimE.J., KimY.H., et al. In vivo effects of preservative-free and preserved prostaglandin analogs: mouse ocular surface study. Korean J. Ophthalmol. 29:270–279, 2015.
25.
FogagnoloP., DipintoA., VanzulliE.et al. A 1-year randomized study of the clinical and confocal effects of tafluprost and latanoprost in newly diagnosed glaucoma patiens. Adv. Ther. 32:356–369, 2015.
26.
SuzukiK., TeranishiS., SagaraT.et al. Safety and efficacy of benzalkonium chloride-optimized tafluprost in Japanese glaucoma patients with existing superficial Punctate Keratitis. J. Glaucoma. 24:e145–e150, 2015.
27.
AmmarD.A., NoeckerR.J., and KahookM.Y.Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv. Ther. 27:837–845, 2010.
28.
LiangH., Brignole-BaudouinF., Rabinovich-GuilattL., et al. Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: an in vivo study in rabbits. Mol. Vis. 14:204–216, 2008.
29.
DaullP., Laurence FerailleP.E., and GarrigueJ.S.Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping. J. Ocul. Pharmacol. Ther. 32:109–118, 2016.
30.
NagelhoutT.J., GamacheD.A., RobertsL., BradyM.T., and YanniJ.M.Preservation of tear film integrity and inhibition of corneal injury by dexamethasone in a rabbit model of lacrimal gland inflammation-induced dry eye. J. Ocul. Pharmacol. Ther. 21:139–148, 2005.
31.
LiN., DengX., GaoY., ZhangS., HeM., and ZhaoD.Establishment of the mild, moderate and severe dry eye models using three methods in rabbits. BMC Ophthalmol. 5:13–50, 2013.
32.
EP04292645 & 20041109. Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential. Owner: Novagali Pharma SA, FR. Inventors: Bague Severine, FR; Garrigue Jean-Sebastian, FR; Lambert Gregory, FR; Philips Betty, FR; Rabinovich-Guilatt Laura, FR.
33.
EP000002389939A1. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions Owner: Novagali Pharma SA, FR. Inventors: Baudouin Christophe, FR; Daull Philippe, FR; Garrigue Jean-Sebastian, FR; Lallemand Frederic, FR.
34.
SchrageN.F., AbuS.S., HermannsL., PanfilC., and DutescuR.M.Irrigation with phosphate-buffered saline causes corneal calcification during treatment of ocular burns. Burns. 45:1871–1879, 2019.
